TY - JOUR
T1 - Adverse effects of androgen deprivation therapy in patients with prostate cancer
T2 - Focus on metabolic complications
AU - Tzortzis, Vasileios
AU - Samarinas, Michael
AU - Zachos, Ioannis
AU - Oeconomou, Athanasios
AU - Pisters, Louis L.
AU - Bargiota, Alexandra
N1 - Publisher Copyright:
© 2017, Hellenic Endocrine Society. All rights reserved.
PY - 2017/4/1
Y1 - 2017/4/1
N2 - Prostate cancer is the most common cancer among men and androgen deprivation therapy (ADT) is the most effective treatment for this disease. The cornerstone of the treatment of prostate cancer is inhibition of testosterone production which interrupts testosterone-induced growth of the prostate tumor. The dramatic decrease in testosterone levels, however, has several undesirable effects on the metabolic profile and bone metabolism and can also lead to fatigue, loss of libido, gynecomastia, and anemia, provoke vasomotor flushing, and generally affect the quality of life. Due to the long-term survival rates of patients with prostate cancer, treatment-related adverse effects are highly relevant and thus, in each clinical setting, the benefits of ADT must be weighed against treatment-related adverse effects. The current review focuses on the more recently described metabolic complications of androgen deprivation therapy, including obesity, diabetes, lipid alterations, metabolic syndrome, and cardiovascular disease. In addition, it provides practical management recommendations drawn from the available guidelines issued by the American Diabetes Association and American Heart Association.
AB - Prostate cancer is the most common cancer among men and androgen deprivation therapy (ADT) is the most effective treatment for this disease. The cornerstone of the treatment of prostate cancer is inhibition of testosterone production which interrupts testosterone-induced growth of the prostate tumor. The dramatic decrease in testosterone levels, however, has several undesirable effects on the metabolic profile and bone metabolism and can also lead to fatigue, loss of libido, gynecomastia, and anemia, provoke vasomotor flushing, and generally affect the quality of life. Due to the long-term survival rates of patients with prostate cancer, treatment-related adverse effects are highly relevant and thus, in each clinical setting, the benefits of ADT must be weighed against treatment-related adverse effects. The current review focuses on the more recently described metabolic complications of androgen deprivation therapy, including obesity, diabetes, lipid alterations, metabolic syndrome, and cardiovascular disease. In addition, it provides practical management recommendations drawn from the available guidelines issued by the American Diabetes Association and American Heart Association.
KW - Androgen deprivation therapy
KW - Diabetes
KW - Metabolic complications
KW - Prostate cancer
UR - http://www.scopus.com/inward/record.url?scp=85026430772&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026430772&partnerID=8YFLogxK
U2 - 10.14310/horm.2002.1727
DO - 10.14310/horm.2002.1727
M3 - Review article
C2 - 28742500
AN - SCOPUS:85026430772
SN - 1109-3099
VL - 16
SP - 115
EP - 123
JO - Hormones
JF - Hormones
IS - 2
ER -